News & Updates
Filter by Specialty:
LSM improves prediction of cholangitis outcomes
Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) is independently associated with primary biliary cholangitis (PBC) outcomes, a study has shown.
LSM improves prediction of cholangitis outcomes
28 Nov 2022
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
27 Nov 2022
Which factors raise HCC risk in patients with cured HCV?
Predictors of hepatocellular carcinoma (HCC) differ in patients with virologically cured hepatitis C virus (HCV) infection with and without cirrhosis, according to a study. However, changes in fibrosis-4 (FIB-4) scores over time are associated with HCC risk in both cohorts.
Which factors raise HCC risk in patients with cured HCV?
24 Nov 2022
Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
Among patients with chronic hepatitis B (CHB), treatment with entecavir (ETV) and Biejia-Ruangan compound (BRC), an antifibrotic traditional Chinese medicine, helps reduce the risk of hepatocellular carcinoma (HCC), a recent study reports.
Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
22 Nov 2022
H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
Among patients with nonalcoholic fatty liver disease (NAFLD), eradication treatment against Helicobacter pylori may help improve liver steatosis and metabolic parameters, a recent study has found.
H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
20 Nov 2022
Noninvasive scores use LSM to detect cirrhosis, advance fibrosis in NAFLD
Using liver stiffness measurements (LSM) combined with routine clinical parameters, Agile 3+, and Agile 4, both noninvasive scoring methods, can accurately identify advanced fibrosis (AF) and cirrhosis, respectively, in patients with nonalcoholic fatty liver disease (NAFLD), reports a new study.
